文献速递消化道肿瘤与早癌消化内镜

早期胃癌非治愈性内镜切除后的长期结局:追加内镜治疗的最佳时机

Long-term outcomes after noncurative endoscopic resection of early gastric cancer: the optimal time for additional endoscopic treatment.
PubMed 文献 · Gastrointest Endosc · 2017-10-12

回顾性分析512例早期胃癌非治愈性内镜黏膜下剥离术(ESD)患者,中位随访79.0±55.7个月。追加手术组癌症特异性生存率和无病生存率均显著优于其他内镜治疗组和观察组;仅水平切缘阳性时,3个月内追加内镜治疗与局部复发风险降低显著相关(HR 0.017)。

要点

  • 追加手术组癌症特异性生存率96.7%、无病生存率92.5%,均显著优于其他内镜治疗组和观察组。
  • 仅水平切缘阳性时,内镜治疗组局部复发无病生存率89.2%显著高于观察组69.1%。
  • 多因素分析显示3个月内追加内镜治疗与局部复发风险降低显著相关(HR 0.017)。

核心结论

  • 非治愈性ESD患者中,追加手术显示更好的长期结局;当水平切缘阳性为唯一非治愈因素时,可考虑3个月内追加内镜治疗以改善无病生存。

研究设计与样本

  • 回顾性分析2527例因早期胃癌行胃ESD患者中512例(20.3%)非治愈性切除者,非治愈性切除定义为组织学切缘阳性、淋巴血管浸润或超出ESD扩大适应证。

主要发现

  • 平均随访79.0±55.7个月,264例(51.6%)追加手术、50例(9.8%)追加内镜治疗、198例(38.7%)观察。
  • 癌症特异性生存率手术组96.7% vs 其他内镜治疗组86.8% vs 观察组86.2%(P=.030)。
  • 无病生存率手术组92.5% vs 其他内镜治疗组73.6% vs 观察组63.0%(P<.001)。
  • 排除手术患者后,内镜治疗组与观察组无病生存率无显著差异(73.6% vs 63.0%,P=.548)。
  • 仅水平切缘阳性患者中,内镜治疗组局部复发无病生存率高于观察组(89.2% vs 69.1%,P=.023)。

关键数值与推荐

  • 多因素分析显示3个月内追加内镜治疗与局部复发风险降低显著相关(HR 0.017,95%CI 0.002-0.260,P=.003)。

临床怎么用

  • 非治愈性ESD后追加手术与更好的长期结局相关;当水平切缘阳性为唯一非治愈因素时,作者认为可考虑3个月内追加内镜治疗以改善无病生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We aimed to evaluate long-term outcomes with noncurative endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) and surveillance strategies such as the optimal time for additional endoscopic treatment in patients with noncurative ESD. METHODS: Of 2527 patients who underwent gastric ESD for EGC, 512 (20.3%) patients with noncurative resection were reviewed. Noncurative resection is defined as positive resected margins on histology, lymphovascular infiltration, or beyond the expanded criteria for ESD. RESULTS: The mean ± standard deviation follow-up duration was 79.0 ± 55.7 months. A total of 264 patients (51.6%) and 50 patients (9.8%) underwent surgery and endoscopic treatment after noncurative resection, respectively, whereas 198 patients (38.7%) were observed. Cancer-specific survival and disease-free survival rates were significantly different among the surgery, other endoscopic treatment, and observation groups (96.7%, 86.8%, and 86.2%, respectively; P =.030; and 92.5%, 73.6%, and 63.0%, respectively; P < .001). When patients who underwent surgery were excluded, the disease-free survival rate of recurrence was not significantly different between the endoscopic treatment and observation groups (73.6% vs 63.0%; P = .548). To exclude the potential for the presence of lymph node metastasis, we further analyzed disease-free survival of local recurrence by comparing the patients with only a positive lateral resection margin. The disease-free survival rate was higher in the endoscopic treatment group than in the observation group (89.2% vs 69.1%; P = .023). Moreover, additional endoscopic treatment within 3 months showed significant associations with lower risk of local recurrence on multivariate analysis (hazard ratio, 0.017; 95% confidence interval, 0.002-0.260; P = .003). CONCLUSIONS: In patients with noncurative ESD, additional surgery showed a better long-term outcome; moreover, when a positive lateral resection margin was the only noncurative factor, additional endoscopic treatment within 3 months could be considered to improve disease-free survival.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Jeon MY, Park JC, Hahn KY, et al. Long-term outcomes after noncurative endoscopic resection of early gastric cancer: the optimal time for additional endoscopic treatment. Gastrointest Endosc. 2017. PMID: 29031882. doi:10.1016/j.gie.2017.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。